N. prodotti: 0
Totale ordine: € 0,00
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,632
Online ISSN 1827-191X
Deloose K. 1, Bosiers M. 1, Callaert J. 1, Verbist J. 2, Vermassen F. 3, Scheinert D. 4, Torsello G. 5, Peeters P. 2
1 Department of Vascular Surgery, AZ Sint‐Blasius, Dendermonde, Belgium;
2 Department of Cardiovascular and Thoracic Surgery, Imelda Hospital, Bonheiden, Belgium;
3 Department of Thoracic and Vascular Surgery, University Hospital Gent, Gent, Belgium;
4 Department of Angiology, Leipzig Heart Center, Leipzig, Germany;
5 Department of Vascular Surgery, St. Franziskus Hospital and University Hospital of Münster, Münster, Germany
AIM: The MISAGO ILIAC study is a prospective, non‐randomized, multi‐center, bi‐national, monitored trial, conducted at 3 hospitals in Belgium and 2 hospitals in Germany. This manuscript reports the findings up to 12‐month follow‐up time for the total cohort. The primary endpoint of the study is primary potency, defined as a target lesion without a hemodynamically significant stenosis on duplex ultrasound (>50%, peak systolic velocity ratio no greater than 2.0) and without target lesion revascularization (TLR), within 12 months.
METHODS: Between September 2011 and April 2012, 120 patients with TASC II Class A or TASC II Class B aortoiliac lesions were included. The cumulative lesion length in the overall population was 45.49 mm with a maximum stenosis pre‐treatment of 83.76%. The demographic data were compatible for the TASC II Class A and TASC II Class B cohort. One patient with a TASC II class C was included as a protocol deviation.
RESULTS: The primary patency rate for the total patient population was 97.4%. The primary patency rates at 12 months for the TASC II Class A and TASC II Class B(C) lesions were respectively 98.3% and 96.6%. No statistical significant difference was shown when comparing these 2 groups (p=0.6407).
CONCLUSION: Our findings confirm that nowadays primary stenting with modern generation stents replaced the more invasive surgery as the golden standard treatment for patients with TASC II Class A and B aortoiliac lesions.